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1. INTRODUCTION {#cam43230-sec-0001}
===============

Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed malignancy and third most common cause of cancer‐related mortality worldwide.[^1^](#cam43230-bib-0001){ref-type="ref"} Patients with early‐stage HCC (tumor size \< 2 cm) could expect more than 70% of 5‐year survival rate after curative treatment.[^2^](#cam43230-bib-0002){ref-type="ref"} Conversely, patients with advanced‐stage HCC are eligible only for palliative treatments and show a poor prognosis with average survival of 1‐2 years.[^3^](#cam43230-bib-0003){ref-type="ref"} Therefore, detection of HCC at early stage is important to improve survival of patients. Liver professional societies, including the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL), recommend HCC surveillance every 6 months to detect HCC at early stages in patients with increased risk of developing HCC.[^4^](#cam43230-bib-0004){ref-type="ref"}, [^5^](#cam43230-bib-0005){ref-type="ref"}, [^6^](#cam43230-bib-0006){ref-type="ref"} Most of the practical guidelines recommend abdominal ultrasound (US) as a major HCC surveillance tool; however, the use of serum alpha‐fetoprotein (AFP) as an adjunct surveillance test remains controversial due to its low sensitivity and suboptimal cost‐effectiveness in detection of early‐stage HCC.[^4^](#cam43230-bib-0004){ref-type="ref"} Reliable serum biomarkers for early‐stage HCC are urgently required for improving the effectiveness of HCC surveillance program.

Recently, liquid biopsy has emerged as a highly promising technology to detect tumor‐derived circulating genetic molecules in blood.[^7^](#cam43230-bib-0007){ref-type="ref"}, [^8^](#cam43230-bib-0008){ref-type="ref"}, [^9^](#cam43230-bib-0009){ref-type="ref"} Exosomes are 30‐ to 100‐nm‐sized extracellular vesicles enclosing genetic materials of the parent (original) cell; they deliver the genetic material from the parent cell to the recipient cell.[^10^](#cam43230-bib-0010){ref-type="ref"}, [^11^](#cam43230-bib-0011){ref-type="ref"} Therefore, exosomes are considered a key player in intercellular communication,[^12^](#cam43230-bib-0012){ref-type="ref"} and exosomal contents are highlighted as major components of liquid biopsy analysis.[^13^](#cam43230-bib-0013){ref-type="ref"} Many studies have been performed to identify cancer cell‐specific exosomal contents to find novel efficient biomarkers and therapeutic targets. Among the exosomal contents, microRNAs (miRs) have attracted profound attention because increasing evidence indicates that the loading of specific miRs into exosome is an actively selected process governed by parent cell characteristics and not a random process.[^14^](#cam43230-bib-0014){ref-type="ref"}, [^15^](#cam43230-bib-0015){ref-type="ref"} Circulating miRs have been highlighted as potential biomarkers in HCC patients.[^16^](#cam43230-bib-0016){ref-type="ref"}, [^17^](#cam43230-bib-0017){ref-type="ref"}, [^18^](#cam43230-bib-0018){ref-type="ref"}

In this study, we aimed to derive a reliable serum exosomal miRs (exo‐miRs) panel to diagnose HCC in early stages. To identify driver oncogenic microRNA (onco‐miR) candidates, systematic integrative analyses were performed using three different RNA sequencing datasets. Diagnostic effectiveness and clinical implications of the selected serum exo‐miR were evaluated in an independent validation cohort.

2. MATERIALS AND METHODS {#cam43230-sec-0002}
========================

2.1. Strategy to identify novel serum exo‐miRs for HCC {#cam43230-sec-0003}
------------------------------------------------------

Figure [1](#cam43230-fig-0001){ref-type="fig"} shows the strategy employed in the present study. Sequencing data from the Catholic University liver disease cohort were used to screen driver onco‐miR candidates (Cohort 1, screening cohort). Cohort 1 consisted of 108 snap‐frozen tissues from 86 subjects categorized based on their liver disease status as follows: 15 normal subjects, 20 with chronic hepatitis (CH), 10 with liver cirrhosis (LC), 18 with well‐differentiated HCC (Edmonson grade 1, wHCC), and 45 with moderate to poorly differentiated HCC (≥Edmonson grade 2, mpHCC). Expression of onco‐miRs selected in Cohort 1 was validated using two different public RNA sequencing (RNA‐seq) datasets from Tsinhua liver cancer hepatocellular carcinoma (LIHC) and the cancer genome atlas (TCGA) LIHC. The expressions of selected onco‐miRs in serum exosome were evaluated using qRT‐PCR in the Ajou university hospital liver disease cohort (720 serum samples from 168 subjects). The Ajou university hospital liver disease cohort was divided into two cohorts: Cohort 2 (test cohort) and Cohort 3 (validation cohort). Expression of onco‐miRs in serum exosome was tested in Cohort 2 (144 serum samples from 24 subjects). And, serum exo‐miRs with area under the receiving operator curve (AUROC) \>0.8 in Cohort 2 were entered into the validation study using Cohort 3(576 serum samples from 144 subjects. AUROCs of the selected serum exo‐miRs were compared with those of serum AFP in the entire Ajou university hospital liver disease cohort. The serum panels using serum exo‐miRs and AFP were derived by logistic regression analysis, and the diagnostic performance of the selected serum panel was evaluated in Ajou university hospital liver disease cohort.

![Strategy to identify novel serum exosomal microRNA for diagnosing HCC. AFP, alpha‐fetoprotein; CH, chronic hepatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; miRNA, microRNA; mpHCC, moderate to poorly differentiated hepatocellular carcinoma; mUICC, modified Union for International Cancer Control; NGS, next‐generation sequencing; NL, normal; qRT‐PCR, quantitative real‐time polymerase chain reaction; RNA, ribonucleic acid; seq, sequencing; TCGA LIHC, The Cancer Genome Atlas Liver Hepatocellular Carcinoma; wHCC, well‐differentiated hepatocellular carcinoma](CAM4-9-5459-g001){#cam43230-fig-0001}

2.2. Clinical information of the cohorts and clinical term definitions {#cam43230-sec-0004}
----------------------------------------------------------------------

Detailed clinicopathological information of the Catholic university liver disease cohort is described in a previously published article.[^19^](#cam43230-bib-0019){ref-type="ref"} Baseline clinicopathological characteristics of cohorts 2 and 3 are detailed in Table [1](#cam43230-tbl-0001){ref-type="table"}. Serum samples and the corresponding clinical data, which were collected between January 2014 and December 2018, were obtained from the Biobank of Ajou university Hospital, a member of Korea Biobank Network. According to the definitions, the subjects were grouped into normal healthy individuals, patients with CH, patients with LC, and patients with HCC. Normal control was defined as 18‐ to 50‐year‐old subjects without any past medical history who visited the A Health Promotion Center for regular health check‐ups and showed completely normal health results. Patients with CH were defined as those with elevated aspartate aminotransferase (AST)/alanine aminotransferase (ALT) for more than six consecutive months. Patients with LC were diagnosed based on clinical findings, radiologic data, and/or histological findings.[^20^](#cam43230-bib-0020){ref-type="ref"} Diagnosis of HCC was determined according to the AASLD practice guidelines.[^4^](#cam43230-bib-0004){ref-type="ref"} Clinical data collected pertained to age, gender, etiology of liver disease, AST level, ALT level, platelet count, serum AFP level, serum albumin level, serum bilirubin level, and international normalized ratio (INR). Tumor size, tumor numbers, presence of vascular invasion, and tumor stage according to the modified Union for International Cancer Control (mUICC) staging system were investigated in HCC patients.[^21^](#cam43230-bib-0021){ref-type="ref"} Early‐stage HCC was defined as single tumor \<2 cm in diameter, which was equivalent to mUICC stage I. High‐risk condition of developing HCC was defined as chronic hepatitis or LC. Disease‐free survival (DFS) was defined as the time from complete response after curative treatment to cancer recurrence. Overall survival (OS) was defined as the time from diagnosis of HCC to death from any cause.

###### 

Baseline characteristics of the included patients

  Variables                         Cohort 2 (n = 24)   Cohort 3 (n = 144)                                                                                                              
  --------------------------------- ------------------- -------------------- ----------------- ------------------------------------- ---------------- ---------------- ---------------- --------------------------------------------
  Age (y), mean ± SD                33.8 ± 4.1          44.8 ± 6.1           54.75 ± 13.40     53.4 ± 11.17                          34.3 ± 7.7       45.0 ± 12.1      53.6 ± 10.4      55.1 ± 8.7
  Male gender, n (%)                0 (0)               1 (25)               0 (0)             10 (83.3)                             3 (13.6)         11 (50)          18 (64.3)        58 (80.6)
  AST, IU/mL                        18.00 ± 0.00        25.75 ± 10.34        65.75 ± 46.09     86.25 ± 139.29                        16.36 ± 4.19     52.68 ± 55.25    87.11 ± 106.39   75.01 ± 95.24
  ALT, IU/mL                        11.33 ± 2.30        26.00 ± 14.02        52.75 ± 53.29     43.75 ± 34.07                         14.09 ± 8.82     60.86 ± 70.27    80.82 ± 105.44   48.53 ± 61.82
  Platelet, ×10^9^/L                335.00              180.33 ± 49.94       139.00 ± 120.95   189.42 ± 92.17                        282.20 ± 34.65   192.95 ± 43.98   123.81 ± 72.12   157.79 ± 78.74
  AFP (ng/mL), mean ± SD            1.80 ± 0.29         4.20 ± 1.59          14.7 ± 11.94      8705.94 ± 19 590.66                   1.77 ± 0.79      13.90 ± 19.65    77.24 ± 142.09   4164.74 ± 14 646.97
  Etiology, n (%)                                       4/0/0/0              4/0/0/0           12/0/0/0                                               21/1/0/0         21/3/2/0         65/3/3/1
  HBV/HCV/alcohol/others                                                                                                                                                                
  Albumin (g/L), mean ± SD                              4.73 ± 0.24          4.4 ± 0.54        4.06 ± 0.58                                            4.59 ± 0.38      3.93 ± 0.53      4.25 ± 0.54
  Bilirubin (mg/dL), mean ± SD                          0.55 ± 0.31          0.70 ± 0.29       0.71 ± 0.45                                            0.82 ± 0.31      1.16 ± 1.07      1.59 ± 4.25
  INR, mean ± SD                                        1.09 ± 0.06          1.21 ± 0.02       1.09 ± 1.10                                            1.02 ± 0.05      1.24 ± 0.19      1.60 ± 2.13
  Modified UICC stage, n (%)                                                                   3(25)/3(25)/2(16.7)/2(16.7)/2(16.7)                                                      24(33.3)/14(19.4)/18(25.0)/10(13.9)/6(8.3)
  I/II/III/IVa/Ivb                                                                                                                                                                      
  Vascular invasion, n (%) Yes/No                                                              5(41.7)/5(41.7)                                                                          24(33.3)/26(36.1)

Abbreviations: CH, chronic hepatitis; LC, liver cirrhosis; HCC, hepatocellular carcinoma; AST, aspartate transaminase; ALT, alanine transaminase; AFP, alpha‐fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; UICC, Union for International Cancer Control.
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2.3. NGS RNA‐seq data analysis and publicly available genomic data analysis {#cam43230-sec-0005}
---------------------------------------------------------------------------

For the large‐scale next‐generation sequencing RNA‐seq analysis, total RNA was extracted using TRIzol reagent (Invitrogen) from frozen liver tissues of Cohort 1 patients. RNA quality control was performed with the Agilent Bioanalyzer system (Agilent Technologies, Santa Clara, CA, USA). The library sequencing was followed by library quality check using the Agilent Bioanalyzer system. The sequencing was performed on Illumina HiSeq2000 machines (Illumina) using the standard Illumina protocol. All sequenced reads were checked for quality. To recapitulate the expression level of miRNA in HCC, genomic data were obtained from TCGA LIHC and the GEO database of the NCBI (Accession Numbers: [GSE76903](http://GSE76903), Tsinghua LIHC). Level 3 miRNA expression data of TCGA LIHC miRNA‐seq V2 were log2 transformed \[log2(TPM + 1)\] and used to assess the gene expression levels.

2.4. Exosome isolation from the peripheral blood of patients {#cam43230-sec-0006}
------------------------------------------------------------

Serum was collected from the included subjects. It was aliquoted in 1 mL tubes and stored at −80°C for subsequent exosome isolation. Serum exosome was extracted using ExoQuick (System Biosciences). Exosomal RNA was isolated from the serum using SeraMir™ Exosome RNA Amplification Kit (System Biosciences).

2.5. Quantitative real‐time PCR (qRT‐PCR) {#cam43230-sec-0007}
-----------------------------------------

The expression of serum exo‐miRs was evaluated using qRT‐PCR. cDNA synthesis was performed using miScript RT II kit (QIAGEN). Furthermore, qRT‐PCR was performed using amfiSure qGreen Q‐PCR Master Mix and monitored in real time using CFX Connect Real‐Time PCR Detection System (Bio‐Rad Laboratories). miR‐1228‐3p was used as an internal control. The relative standard curve method (2^−ΔΔCT^) was used to determine the relative expression. The sequence of each miRNA was confirmed in miRBase database (<http://www.mirbase.org>; Table S1). All measurements were confirmed three times. Primer sequences used in the study are illustrated in Table S1.

2.6. Statistical analysis {#cam43230-sec-0008}
-------------------------

All experiments were performed at least three times, and all samples were analyzed in triplicates. Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM). Statistical significance of the difference between experimental groups was assessed by paired or unpaired Welch\'s *t* test. IBM SPSS software version 22.0 (SPSS Inc) and GraphPad Prism version 7.01 were used for statistical analysis. Statistical significance was established at *P* \< .05. Chi‐square test (two‐sided) was used to assess the association between categorical parameters. Survival curves were plotted using the Kaplan‐Meier method, and significant difference between the survival curves was determined using the Log‐rank test. Receiver operating characteristic (ROC) curves were analyzed to evaluate sensitivity, specificity, and respective AUROCs with 95% confidence interval (CI) for each candidate biomarker.

3. RESULTS {#cam43230-sec-0009}
==========

3.1. Identification of potential driver onco‐miRs by integrative analysis of sequencing data from three different RNA‐seq dataset {#cam43230-sec-0010}
---------------------------------------------------------------------------------------------------------------------------------

To identify potential driver onco‐miRs, tissue‐small RNA sequencing data from Cohort 1 were analyzed, and HCC‐specific onco‐miR signatures were identified. To validate expression of selected miRs in Cohort 1, integrative analyses with two other different public RNA‐seq datasets, from Tsinghua LIHC and TCGA LIHC, were performed. Tsinghua LIHC data were used to verify expression of selected miRs, and TCGA LIHC data were used to select miRs associated with prognosis by performing survival analysis (Figure [2A](#cam43230-fig-0002){ref-type="fig"}).

![Integrative analysis of tissue sequencing data from three independent cohorts to identify onco‐miRs of HCC. A, Pipeline of gene expression analysis for identifying oncogenic miRs for HCC development. B, Venn diagram analysis of significantly overexpressed miRs in each disease status compared to normal subjects in Catholic LIHC cohort (Welch\'s t‐test, *P* \< .05 and ≥1.3 fold). C, Venn diagram analysis to identify commonly overexpressed microRNAs in HCC tissues in Catholic LIHC and Tsinghua LIHC. D, Heatmaps of 71 microRNAs which were significantly overexpressed in HCC tissues in three different RNA sequencing datasets. E, Receiving operating curves of microRNAs with AUROC \> 0.7 among 71 microRNAs in each HCC RNA sequencing datasets. CH, chronic hepatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; LIHC, Liver Hepatocellular Carcinoma; miRNA, microRNA; mpHCC, moderate to poorly differentiated hepatocellular carcinoma; ROC, receiving operation curve; TCGA_LIHC, The Cancer Genome Atlas Liver Hepatocellular Carcinoma; wHCC, well‐differentiated hepatocellular carcinoma](CAM4-9-5459-g002){#cam43230-fig-0002}

First, gene expression profiling of Cohort 1 sequencing data was performed. Significantly upregulated miRs compared to normal group (Welch\'s *t* test, *P* \< .05 and ≥1.3 fold) was identified in each disease status. Figure [2B](#cam43230-fig-0002){ref-type="fig"} shows the distribution of upregulated miRs in a Venn diagram according to liver disease status compared to normal group. A total of 140 miRs were overexpressed at HCC status, but not overexpressed at nontumor status in Cohort 1. Tsinghua LIHC data were analyzed, and a total of 305 miRs (Welch\'s *t* test, *P* \< .05 and ≥1.5 fold) overexpressed in HCC tissues when compared with nontumor tissues were identified. Integrative analysis of Cohort 1 and Tsinghua LIHC data revealed 71 commonly overexpressed miRs in HCC (Figure [2C](#cam43230-fig-0002){ref-type="fig"}). Figure [2D](#cam43230-fig-0002){ref-type="fig"} shows the heatmaps of the expressions of the 71 miRs in Cohort 1, Tsinghua LIHC, and TCGA LIHC. Figure [2E](#cam43230-fig-0002){ref-type="fig"} shows the receiving operator curves (ROCs) of the 71 miRs for diagnosing HCC in each cohort. AUROCs of 71 miRs were calculated, and the miRs with AUROC ≥ 0.7 in each cohort were selected for the next step (Figure [2E](#cam43230-fig-0002){ref-type="fig"}). Twenty‐six miRs, listed in Table [S2](#cam43230-sup-0003){ref-type="supplementary-material"}, were identified as commonly overexpressed onco‐miRs in HCC tissues with AUROC \> 0.7 in Cohort 1, Tsinghua LIHC, and TCGA LIHC (Figure S1). The 26 miRs were scored to evaluate potential as the driver onco‐miR. Table [S2](#cam43230-sup-0003){ref-type="supplementary-material"} enlists 26 miRs and their clinicopathological scores. The miRs associated with OS or DFS were assigned 1 point, and another 1 point was assigned for the overexpressed miRs in well‐differentiated HCC (Welch\'s *t* test, *P* \< .05 and ≥1.5 fold), assuming that the driver onco‐miR is expressed early in differentiation phase. As a result, 6 of the 26 miRs, including miR‐25‐3p, miR‐140‐3p, miR‐422‐3p, miR‐1269a, miR‐4661‐5p, and miR‐4746‐5p, gained two points and were selected as potential driver onco‐miRs for next step. Figure [3A](#cam43230-fig-0003){ref-type="fig"} shows the expression of the six selected miRs according to liver disease status in the Cohort 1. The six selected miRs were significantly upregulated in HCC tissues compared to nontumor tissues (Welch\'s *t* test, \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001). Figure [3B](#cam43230-fig-0003){ref-type="fig"} shows Kaplan‐Meier survival plot of HCC patients from TCGA LIHC dataset according to expression of six miRs. Patients with overexpressed miR‐25‐3p, miR‐140‐3p, and miR‐423‐3p showed significantly poor OS, whereas patients with overexpressed miR‐1269a, miR‐4661‐5p, and miR‐4746‐5p showed significantly shorter DFS (Log‐rank test, \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001).

![Comparison of miRs expression according to liver disease status and impact on survival. A, Expression of the selected six miRs according to liver disease status in Catholic LIHC cohort. B, Kaplan‐Meier survival analysis of HCC patients to compare overall survival and disease‐free survival according to the tissue expression of six miRs in TCGA LIHC dataset. CH, chronic hepatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; LIHC, Liver Hepatocellular Carcinoma; miR, microRNA; mpHCC, moderate to poorly differentiated hepatocellular carcinoma; TCGA LIHC, The Cancer Genome Atlas Liver Hepatocellular Carcinoma; wHCC, well‐differentiated hepatocellular carcinoma](CAM4-9-5459-g003){#cam43230-fig-0003}

3.2. Expression of the selected six miRs in serum exosome: Test cohort {#cam43230-sec-0011}
----------------------------------------------------------------------

The expression of the six miRs in serum exosomes was evaluated in Cohort 2 (test cohort) to determine whether the selected miRs could be used as a serum biomarker for HCC. Cohort 2 included 24 subjects, including 4 normal subjects (n = 4), 4 patients with CH, 4 patients with LC, 6 patients with mUICCI/II, and 6 patients with mUICC III/IV. Figure [4A](#cam43230-fig-0004){ref-type="fig"} shows the expression value of the selected six serum exo‐miRs in Cohort 2. The expression of serum exo‐miR‐25‐3p, exo‐miR‐1269a, exo‐miR‐4661‐5p, and exo‐miR‐4746‐5p was significantly upregulated in the HCC group compared to nontumor status. The AUROCs were calculated, and four of the six miRs, including miR‐25‐3p, miR‐1269a, miR‐4661‐5p, and miR‐4746‐5p, showed AUROC \> 0.8 (Figure [4B](#cam43230-fig-0004){ref-type="fig"}). Consequently, the four miRs with AUROC \> 0.8 were entered into the validation study using Cohort 3.

![Expression according to liver disease status of the selected serum exo‐miRs and their diagnostic performance for diagnosing HCC. A, Expression of six serum exo‐miRs according to liver disease status in test cohort (Cohort 2). B, AUROC of six exo‐miRs for diagnosing HCC in test cohort (Cohort 2). C, Expression of four serum exo‐miRs according to liver disease status in validation cohort (Cohort 3). D, AUROC of four exo‐miRs for diagnosing HCC in validation cohort (Cohort 3). 95% CI, 95% confidence interval; AUC, the area under a receiver operating characteristic; AUROC, the area under a receiver operating characteristic; CH, chronic hepatitis; Exo‐miRs, exosomal microRNA; HCC, hepatocellular carcinoma; LC, liver cirrhosis; mUICC, modified Union for International Cancer Control](CAM4-9-5459-g004){#cam43230-fig-0004}

3.3. Validation of the four serum exo‐miRs in Cohort 3 {#cam43230-sec-0012}
------------------------------------------------------

Cohort 3 included 144 subjects, comprising 22 normal subjects, 20 patients with CH, 28 patients with LC, 34 patients with mUICC I/II, and 36 patients with mUICC III/IV. The expression value of the selected four serum exo‐miRs---miR‐25‐3p, miR‐1269a, miR‐4661‐5p, and miR‐4746‐5p---was evaluated by qRT‐PCR. Figure [4C](#cam43230-fig-0004){ref-type="fig"} shows the expression values of the four serum exo‐miRs according to the disease status in Cohort 3. All four miRs were significantly upregulated in HCC patients compared to individuals with no tumor (Welch\'s *t* test, \**P* \< .0 5, \*\**P* \< .01, \*\*\**P* \< .001). Figure [4D](#cam43230-fig-0004){ref-type="fig"} shows ROCs of the four serum exo‐miRs for diagnosing HCC. Serum exo‐miR‐4661‐5p, with an AUROC value of 0.918 (95% CI: 0.860‐0.958), was identified as the most accurate diagnostic marker for HCC. The AUROC values of the other serum exo‐miRs were as follows: 0.758 for miR‐25‐3p (95% CI: 0.679‐0.827), 0.844 for miR‐1269a (95% CI: 0.773‐0.900), and 0.687 for miR‐4746‐5p (95% CI: 0.542‐0.707).

3.4. Comparison of diagnostic power of the selected four serum exo‐miRs and serum AFP {#cam43230-sec-0013}
-------------------------------------------------------------------------------------

To compare the diagnostic power of serum AFP and the four selected exo‐miRs, AUROC of each serum marker was evaluated in the entire Ajou university hospital liver disease cohort (Figure [5](#cam43230-fig-0005){ref-type="fig"}). AUROC of AFP for HCC diagnosis was 0.704, whereas those of serum exo‐miR‐25‐3p, exo‐miR‐1269a, exo‐miR‐4661‐5p, and exo‐miR‐4746‐5p were 0.758, 0.848, 0.917, and 0.660, respectively. Serum exo‐miR‐1269a and miR‐4661‐5p showed significantly better performance than AFP (Figure [5A](#cam43230-fig-0005){ref-type="fig"}). In diagnosing HCC among the patients with CH and LC, serum exo‐miR‐25‐3p, miR‐1269a, and miR‐4661‐5p showed significantly greater AUROC values (0.690, 0.829, and 0.910, respectively) than serum AFP (0.597).

![Diagnostic performance of serum exo‐miRs for diagnosing HCC in qRT‐PCR cohort. A, AUROCs for diagnosing HCC at all stages from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). B, AUROCs for diagnosing HCC with mUICC stage I or II from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). C, AUROCs for diagnosing HCC with mUICC stage I from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). AFP, alpha‐fetoprotein; AUROC, the area under a receiver operating characteristic; CH, chronic hepatitis; Exo‐miRs, exosomal microRNA; HCC, hepatocellular carcinoma; LC, liver cirrhosis; miR, microRNA; mUICC, modified Union for International Cancer Control; qRT‐PCR, quantitative real‐time polymerase chain reaction](CAM4-9-5459-g005){#cam43230-fig-0005}

For distinguishing mUICC stage I/II HCC from nontumor status, serum exo‐miR‐1269a (AUROC = 0.853) and 4661‐5p (AUROC = 0.910) showed significantly greater AUROC values than serum AFP (0.597). For distinguishing mUICC stage I/II stage HCC from patients with CH or LC, serum exo‐miR‐1269a and 4661‐5p also showed greater AUROC value than serum AFP (AUROC; miR4661‐5p = 0.910, miR‐1269a 0.583, AFP = 0.540; Figure [5B](#cam43230-fig-0005){ref-type="fig"}).

Diagnostic accuracy of the serum exo‐miRs and AFP for diagnosing early‐stage HCC, which is equivalent to mUICC stage I, was also evaluated (Figure [5C](#cam43230-fig-0005){ref-type="fig"}). Serum exo‐miR‐25 (AUROC = 0.812), exo‐miR‐1269a (AUROC = 0.684), and exo‐miR‐4661‐5p (AUROC = 0.923) showed significantly better AUROC values than serum AFP (AUROC = 0.541). Subgroup analysis was performed to determine whether the candidate serum exo‐miRs could distinguish patients with early‐stage HCC from patients at high risk for developing HCC. Consequently, serum exo‐miR‐1269a (AUROC = 0.837) and exo‐miR‐4661 (AUROC = 0.924) showed significantly greater accuracy than serum AFP (AUROC = 0.604) in diagnosing early‐stage HCC among the patients with CH or LC.

3.5. Development of diagnostic panel for HCC {#cam43230-sec-0014}
--------------------------------------------

To derive most potent diagnostic panel, various combinations of the four serum exo‐miRs and serum AFP were attempted. Panels were made using linear logistic regression. The panel configuration was limited to two biomarkers considering their usability in clinical practice. The list of derived panels and their AUROCs is shown in Table S3. The cut‐off values of derived panels for measuring sensitivity and specificity are listed in Table [S4](#cam43230-sup-0005){ref-type="supplementary-material"}. Cut‐off values for sensitivity and specificity were determined at the maximum Youden index. The combination of serum exo‐miR‐4661 and exo‐miR‐4746 showed most efficient diagnostic power for diagnosing HCC (AUROC = 0.942, 95% CI = 0.908‐0.975; Panel A). The second‐best combination was of serum AFP and serum exo‐miR‐4661 (AUROC = 0.921, 95% CI = 0.821‐0.927; Panel B). Table [2](#cam43230-tbl-0002){ref-type="table"} demonstrates the comparison of the diagnostic performance of Panel A, Panel B, and serum AFP in various situations. Figure [6](#cam43230-fig-0006){ref-type="fig"} shows the comparison of ROC curves between the derived serum panels and serum AFP (Figure [6A‐C](#cam43230-fig-0006){ref-type="fig"}). Panels A and B showed significantly superior performance to serum AFP in all situations (*P* \< .0001). To diagnose early‐stage HCC, the AUROC of Panel A was measured as 0.947 (95% CI = 0.889‐0.980), with a sensitivity of 81.8% and specificity of 91.7% (Figure [6C](#cam43230-fig-0006){ref-type="fig"}, left). In addition, in patients at high risk for HCC, Panel A could distinguish early‐stage HCC with great accuracy (AUROC = 0.954, sensitivity = 86.7%, specificity = 93.1%; Figure [6C](#cam43230-fig-0006){ref-type="fig"}, right). Panel B also showed good diagnostic performance for early‐stage HCC in all included patients (AUROC = 0.925, 95% CI = 0.861‐0.966, sensitivity = 86.7%, specificity = 93.1%) for distinguishing early‐stage HCC patients from those with high risk for developing HCC including CH and LC (AUROC = 0.929, 95% CI = 0.854‐0.973, sensitivity = 70.0%, specificity = 98.3%).

###### 

The area under the receiving operator curves, sensitivity, and specificity of the derived serum panels and serum AFP for diagnosing HCC

                                *P* vs AFP   AUC     95% CI        Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)
  ----------------------------- ------------ ------- ------------- ----------------- ----------------- --------- ---------
  HCC vs Nontumor                                                                                                
  AFP (20 ng/mL)                1            0.704   0.629‐0.772   38.095            71.429            57.143    53.571
  AFP + miR‐4661‐5p             \<.0001      0.921   0.870‐0.957   76.190            95.238            94.118    80.000
  miR‐4661‐5p + miR‐4746‐5p     \<.0001      0.942   0.895‐0.972   84.524            89.286            88.750    85.227
  mUICC I and II vs Nontumor                                                                                     
  AFP (20 ng/mL)                1            0.597   0.507‐0.683   38.095            58.621            57.143    39.535
  AFP + miR‐4661‐5p             \<.0001      0.911   0.847‐0.954   72.619            96.552            96.825    70.886
  miR‐4661‐5p + miR‐4746‐5p     \<.0001      0.945   0.890‐0.977   84.524            91.379            93.421    80.303
  mUICC I vs Nontumor                                                                                            
  AFP (20 ng/mL)                1            0.541   0.445‐0.634   15.909            71.429            22.581    61.856
  AFP + miR‐4661‐5p             \<.0001      0.925   0.861‐0.966   95.455            69.048            61.765    96.667
  miR‐4661‐5p + miR‐4746‐5p     .95          0.947   0.889‐0.980   81.818            91.667            83.721    90.588
  HCC vs CH and LC                                                                                               
  AFP (20 ng/mL)                1            0.597   0.511‐0.678   15.909            58.621            22.581    47.887
  AFP + miR‐4661‐5p             \<.0001      0.921   0.863‐0.959   95.455            72.414            72.414    95.455
  miR‐4661‐5p + miR‐4746‐5p     \<.0001      0.948   0.898‐0.979   93.182            82.759            80.392    94.118
  mUICC I and II vs CH and LC                                                                                    
  AFP (20 ng/mL)                1            0.540   0.439‐0.639   10.000            71.429            11.111    68.966
  AFP + miR‐4661‐5p             \<.0001      0.910   0.837‐0.958   70.000            98.810            95.455    90.217
  miR‐4661‐5p + miR‐4746‐5p     \<.0001      0.951   0.889‐0.984   86.667            90.476            76.471    95.000
  mUICC I vs CH and LC                                                                                           
  AFP (20 ng/mL)                1            0.604   0.494‐0.707   10.000            58.621            11.111    55.738
  AFP + miR‐4661‐5p             \<.0001      0.929   0.854‐0.973   70.000            98.276            95.455    86.364
  miR‐4661‐5p + miR‐4746‐5p     \<.0001      0.954   0.887‐0.987   86.667            93.103            86.667    93.103

Abbreviations: AFP, alpha‐fetoprotein; CH, chronic hepatitis; HCC, hepatocellular carcinoma; LC, liver cirrhosis; miR, microRNA; mUICC, modified Union for International Cancer Control.
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![Diagnostic performance of the serum exo‐miR panels for HCC in qRT‐PCR cohort. A. AUROCs for diagnosing all stage HCC from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). B, AUROCs for diagnosing HCC with mUICC stage I or II from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). C, AUROCs for diagnosing HCC with mUICC stage I from nontumor subjects (normal, chronic hepatitis, and liver cirrhosis; left) and from patients at high risk of developing HCC (chronic hepatitis and liver cirrhosis; right). AFP, alpha‐fetoprotein; AUROC, the area under a receiver operating characteristic; CH, chronic hepatitis; Exo‐miRs, exosomal microRNA; HCC, hepatocellular carcinoma; LC, liver cirrhosis; miR, microRNA; mUICC, modified Union for International Cancer Control; qRT‐PCR, quantitative real‐time polymerase chain reaction](CAM4-9-5459-g006){#cam43230-fig-0006}

3.6. Prognostic implication of the four serum exo‐miRs {#cam43230-sec-0015}
------------------------------------------------------

Prognostic implications of the selected four serum exo‐miRs were evaluated. Serum exo‐miR‐25‐3p expression was found to be gradually increased with tumor stage advancement with statistical significance (Figure [7A](#cam43230-fig-0007){ref-type="fig"}). Upregulation of serum exo‐miR‐25‐3p and exo‐miR‐4661‐5p was significantly associated with vascular invasion (*P* = .05; Figure [7B](#cam43230-fig-0007){ref-type="fig"}). Kaplan‐Meier analyses were performed to identify prognostic implications of serum exo‐miRs. The patients were divided according to exo‐miR expression value: high expression group and low expression group. Cut‐off values were determined at median expression value of each exo‐miRs. The patients in the high expression group of serum exo‐miR‐25‐3p and serum exo‐miR‐4661‐5p showed significantly poor DFS compared to patients in the low expression group (Figure [7C](#cam43230-fig-0007){ref-type="fig"}).

![Prognostic significance of the 4 serum exo‐miRs in Ajou university hospital liver disease cohort. A, Expression of the serum exo‐miRs according to mUICC stage guidelines. B, Expression of the serum exo‐miRs according to vascular invasion. C, Disease‐free survival according to the expression of the four serum exo‐miRs in the qRT‐PCR cohort. Exo‐miR, exosomal microRNA; HCC, hepatocellular carcinoma; miR, microRNA; mUICC, modified Union for International Cancer Control; qRT‐PCR, quantitative real‐time polymerase chain reaction](CAM4-9-5459-g007){#cam43230-fig-0007}

4. DISCUSSION {#cam43230-sec-0016}
=============

This study derived novel and potent diagnostic serum exo‐miR panels for early‐stage HCC by integrative analysis of three different RNA‐seq datasets and serum exo‐miR expression data. The panels based on serum exo‐miR‐4661‐5p showed potential diagnostic effectiveness for HCC even in early stages with AUROC \> 0.9. To our knowledge, this is the first study to identify serum exo‐miR‐4661‐5p--based panel as a potential diagnostic biomarker for early‐stage HCC.

In previous decades, several studies have showed that exo‐miRs from tumor cells are secreted into systemic circulation; therefore, circulating exo‐miRs have been investigated to develop ideal biomarkers and therapeutic targets in various intractable diseases.[^22^](#cam43230-bib-0022){ref-type="ref"}, [^23^](#cam43230-bib-0023){ref-type="ref"}, [^24^](#cam43230-bib-0024){ref-type="ref"} However, the results of previous studies regarding circulating exo‐miRs have not met expectations probably because they mainly focused on tissue expression data rather than serum data; however, tissue miR expression profile is somewhat different from circulating exo‐miRs expression profiles.[^25^](#cam43230-bib-0025){ref-type="ref"}, [^26^](#cam43230-bib-0026){ref-type="ref"} Therefore, a comprehensive and systematic genome‐wide biomarker discovery approach was planned in this study to find potential driver onco‐miRs which are commonly overexpressed in both HCC tissue and serum exosome. First, we performed integrative analysis of miR expression profile and clinicopathological data of human multistage HCC from three independent RNA‐seq datasets to identify potent driver onco‐miRs. Consequently, four miRs, including miR‐25‐3p, miR‐1269a, miR‐4661‐5p, and miR‐4746‐5p, were identified as commonly overexpressed miRs in both tissue and serum exosome in patients with HCC. We validated these findings and identified that serum exo‐miR‐4661‐5p--based panels were potent diagnostic serum biomarkers for early‐stage HCC. Systematic integrative analysis and validation strategies were the strength of the present study, which led to the successful development of a promising, novel serum exo‐miR panel for HCC.

Diagnosis of HCC at early stages is essential to improve the prognosis of patients with HCC.[^27^](#cam43230-bib-0027){ref-type="ref"}, [^28^](#cam43230-bib-0028){ref-type="ref"} Abdominal US with or without serum AFP is currently the main modality of HCC surveillance despite its sensitivity for early‐stage HCC being only 40%‐50%.[^29^](#cam43230-bib-0029){ref-type="ref"}, [^30^](#cam43230-bib-0030){ref-type="ref"} Recently, a meta‐analysis reported that concomitant use of serum AFP with US could improve the sensitivity for early‐stage HCC from 45% to 63%; however, the role of serum AFP for surveillance of early‐stage HCC remains controversial.[^31^](#cam43230-bib-0031){ref-type="ref"}, [^32^](#cam43230-bib-0032){ref-type="ref"} Therefore, many studies have been performed to find a reliable serum biomarker for early‐stage HCC; however, no biomarker better than serum AFP has been identified.[^33^](#cam43230-bib-0033){ref-type="ref"}, [^34^](#cam43230-bib-0034){ref-type="ref"} A reliable serum biomarker for early‐stage HCC is required to improve HCC surveillance. In this study, we tried to find a reliable biomarker of HCC, and serum exo‐miR‐4661‐5p was identified as an effective biomarker for HCC at all stages, including early stage, with a greater degree of accuracy than serum AFP (AUROC of serum exo‐miR‐4661‐5p = 0.923 vs AUROC of serum AFP = 0.541, *P* \< .0001). In the present study, the sensitivity of serum AFP for early‐stage HCC was only about 10%--15%, whereas that of exo‐miR‐4661‐5p--based serum panel was about 80%‐95% (Table [2](#cam43230-tbl-0002){ref-type="table"}). Based on these findings, we can suggest exo‐miR‐4661‐5p--based serum panel as a more potent and reliable serum biomarker than serum AFP alone for diagnosing early‐stage HCC. Exo‐miR‐4661‐5p--based serum panel may improve the performance of HCC surveillance system in clinical practice. Further external validation in a larger cohort is required to incorporate it in real clinical practice.

To our knowledge, there has been no research regarding the clinical implication and mechanism of miR‐4661‐5p in patients with HCC. This study revealed the clinical implications of serum exo‐miR‐4661‐5p for the first time. It was revealed as a potent diagnostic serum marker of HCC and was also associated with the prognosis of patients with HCC; higher level of serum exo‐miR‐4661‐5p was correlated with poor prognosis of HCC patients. However, the action mechanism of miR‐4661‐5p was not evaluated in this study. Several previous studies have showed that miR‐4661 is a positive regulator of interleukin‐10 (IL‐10) expression in several inflammatory diseases.[^35^](#cam43230-bib-0035){ref-type="ref"}, [^36^](#cam43230-bib-0036){ref-type="ref"} IL‐10 is an anti‐inflammatory cytokine which is encoded by the *IL10* gene.[^37^](#cam43230-bib-0037){ref-type="ref"} Many studies have reported upregulated serum IL‐10 levels and higher expression of *IL10* gene in tissues of patients with HCC compared to non‐tumor status.[^38^](#cam43230-bib-0038){ref-type="ref"}, [^39^](#cam43230-bib-0039){ref-type="ref"} In addition, higher IL‐10 serum level is reportedly inversely correlated with the prognosis of patients with HCC as IL‐10 is a suppressor of antitumor immunity in HCC.[^40^](#cam43230-bib-0040){ref-type="ref"} Based on the results of previous studies and the present study, miR‐4661‐5p would have an oncogenic role in HCC, and it may suppress the antitumor immunity by upregulating the IL‐10 level. Further study is required to elucidate the action mechanism of serum exo‐miR‐4661‐5p in HCC and its correlation with IL‐10 expression levels.

In conclusion, the present study derived potential serum exo‐miR panels for HCC using a systematic, genome‐wide biomarker discovery approach. Serum exo‐miR‐4661‐5p--based panel is a potent diagnostic biomarker for early‐stage HCC and could also be used as a prognostic indicator in patients with HCC. Further mechanism study of exo‐miR‐4661‐5p in HCC and validation study in a large independent external cohort are required.
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